Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: A randomized placebo-controlled trial (END-HF)

Teguh Santoso Sukamto, Ching Wah Siu, Cosphiadi Irawan, Wing Sze Chan, Idrus Alwi, Kai Hang Yiu, Auda Aziz, Yok Lam Kwong, Hung Fat Tse

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Abstract

Prior studies suggest that endomyocardial implantation of autologous bone marrow (BM) mononuclear cell therapy improves symptoms and left ventricular (LV) function in patients with refractory angina; however, the therapeutic efficacy in patients with ischemic cardiomyopathy is unclear. In a randomized, double-blind, placebo-controlled trial, 28 patients with advanced ischemic cardiomyopathy [New York Heart Association III-IV, LV ejection fraction (LVEF) <40 %] were assigned in 2:1 ratio to receive endomyocardial injection of BM cells (100 million, n=19) or placebo (n=9), guided by electroanatomical mapping. After 6 months, there was no significant difference between the two groups in LV ejection fraction (LVEF) and LV end-systolic volume (LVESV), LV infarct volume, and LV peri-infarct ischemic volume as determined by cardiac magnetic resonance imaging or exercise capacity. In conclusion, endomyocardial implantation of autologous BM mononuclear cells did not improve LV function or remodeling in patients with advanced ischemic cardiomyopathy.

Original languageEnglish
Pages (from-to)545-552
Number of pages8
JournalJournal of Cardiovascular Translational Research
Volume7
Issue number6
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Bone marrow cells
  • Heart failure
  • Ischemic cardiomyopathy

Fingerprint

Dive into the research topics of 'Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: A randomized placebo-controlled trial (END-HF)'. Together they form a unique fingerprint.

Cite this